[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2255826T1 - Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov - Google Patents

Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov

Info

Publication number
SI2255826T1
SI2255826T1 SI200332485A SI200332485A SI2255826T1 SI 2255826 T1 SI2255826 T1 SI 2255826T1 SI 200332485 A SI200332485 A SI 200332485A SI 200332485 A SI200332485 A SI 200332485A SI 2255826 T1 SI2255826 T1 SI 2255826T1
Authority
SI
Slovenia
Prior art keywords
antigens
combination
vaccine compositions
neisserial vaccine
neisserial
Prior art date
Application number
SI200332485A
Other languages
English (en)
Inventor
Francois-Xavier Jacques Berthet
Ralph Biemans
Philippe Denoel
Christiane Feron
Carine Goraj
Jan Poolman
Vincent Weynants
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31722002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2255826(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230170A external-priority patent/GB0230170D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Priority claimed from GB0305028A external-priority patent/GB0305028D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI2255826T1 publication Critical patent/SI2255826T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200332485A 2002-08-02 2003-07-31 Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov SI2255826T1 (sl)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230170A GB0230170D0 (en) 2002-12-24 2002-12-24 Vaccine
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0305028A GB0305028D0 (en) 2003-03-05 2003-03-05 Vaccine
EP10177890.0A EP2255826B1 (en) 2002-08-02 2003-07-31 Neisserial vaccine compositions comprising a combination of antigens

Publications (1)

Publication Number Publication Date
SI2255826T1 true SI2255826T1 (sl) 2016-07-29

Family

ID=31722002

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200332262T SI1524993T1 (sl) 2002-08-02 2003-07-31 Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
SI200332485A SI2255826T1 (sl) 2002-08-02 2003-07-31 Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200332262T SI1524993T1 (sl) 2002-08-02 2003-07-31 Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov

Country Status (26)

Country Link
US (9) US7838014B2 (sl)
EP (11) EP1961427A3 (sl)
JP (7) JP2006506467A (sl)
KR (6) KR101140033B1 (sl)
CN (2) CN1671413A (sl)
AU (6) AU2003250204B8 (sl)
CA (4) CA2493124C (sl)
CO (3) CO5680454A2 (sl)
CY (3) CY1114243T1 (sl)
DE (2) DE20321890U1 (sl)
DK (2) DK1524993T3 (sl)
ES (3) ES2537737T3 (sl)
HK (1) HK1077014A1 (sl)
HU (1) HUE029200T2 (sl)
IL (3) IL165660A0 (sl)
IS (3) IS7593A (sl)
LU (1) LU92262I2 (sl)
MX (3) MXPA05001265A (sl)
MY (1) MY149591A (sl)
NO (3) NO20050010L (sl)
NZ (4) NZ574530A (sl)
PL (5) PL216662B1 (sl)
PT (2) PT2255826E (sl)
SI (2) SI1524993T1 (sl)
TW (1) TWI360424B (sl)
WO (4) WO2004014419A1 (sl)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
DK2275553T3 (en) 1999-10-29 2015-08-03 Novartis Vaccines & Diagnostic Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
AU2818101A (en) * 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
US20040092711A1 (en) * 2000-02-28 2004-05-13 Arico Maria Beatrice Hybrid expression of neisserial proteins
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE60236596D1 (de) 2001-07-27 2010-07-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
PL216662B1 (pl) * 2002-08-02 2014-04-30 Glaxosmithkline Biolog Sa Preparat immunogenny
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004032958A1 (en) * 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
NZ546601A (en) 2003-09-19 2010-07-30 Epitopix Llc Compositions comprising at least six isolated metal regulated polypeptides obtainable from campylobacter spp
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323709D0 (en) * 2003-10-09 2003-11-12 Health Prot Agency Modified whole cell,cell extract and omv-based vaccines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2550927A1 (en) 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
ES2344114T3 (es) 2004-05-11 2010-08-18 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Lipooligosacaridos de neisseria meningitidis igtb como adyuvante.
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
GB0428381D0 (en) * 2004-12-24 2005-02-02 Isis Innovation Vaccine
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
AU2006206234B2 (en) * 2005-01-21 2012-01-12 Epitopix, Llc Yersinia spp. polypeptides and methods of use
US9034345B2 (en) * 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2007000322A1 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7955817B2 (en) 2005-09-02 2011-06-07 Glaxosmithkline Biologicals S.A. Vaccine protection assay
EP2333549A3 (en) * 2005-09-05 2011-11-02 GlaxoSmithKline Biologicals s.a. Serum bactericidal assay for n. meningitidis specific antisera
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1962902A2 (en) * 2005-12-06 2008-09-03 Universita Degli Studi di Padova Methods and compositions relating to adhesins as adjuvants
KR101365001B1 (ko) 2005-12-22 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
EP3141261A1 (en) 2006-03-30 2017-03-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP5275982B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US20100285465A1 (en) * 2007-08-02 2010-11-11 Glaxosmithkline Biologicals S.A. Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis
RU2498815C2 (ru) 2007-10-19 2013-11-20 Новартис Аг НАБОР ДЛЯ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ ПРОТИВ Neisseria meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
CA2716706C (en) 2008-03-03 2014-02-18 Irm Llc Compounds and compositions as tlr activity modulators
CN102105166A (zh) * 2008-05-30 2011-06-22 由沃尔特·里德军队研究院军队秘书处为代表的美利坚合众国 脑膜炎球菌多价原始外膜囊泡疫苗、其制备方法和应用
KR101042541B1 (ko) * 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
WO2010027729A2 (en) * 2008-08-25 2010-03-11 Creatv Microtech, Inc. Gonococcal vaccines
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) * 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
CN101759781B (zh) * 2008-12-25 2013-04-03 上海市第六人民医院 一种细菌表层黏附蛋白及其用途
JP5568017B2 (ja) 2008-12-25 2014-08-06 一般財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
AU2010227221B2 (en) * 2009-03-24 2015-01-22 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
EP2429658B1 (fr) * 2009-05-14 2016-04-20 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (LPS) des bactéries à gram-négatif
DK2430151T3 (da) 2009-05-14 2014-09-15 Sanofi Pasteur Meningokokvaccine på basis af lipooligosaccharid (los) fra modificerede stammer af neisseria meningitidis med immuntype l6
EP2429576A1 (fr) * 2009-05-14 2012-03-21 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis
WO2010134225A1 (ja) * 2009-05-20 2010-11-25 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
KR101430283B1 (ko) 2009-09-01 2014-08-14 주식회사이언메딕스 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CA2779839A1 (en) * 2009-11-06 2011-05-12 Children's Hospital & Research Center At Oakland T-cell stimulating protein b and methods of use
EP2512478B1 (en) 2009-12-15 2017-04-19 GlaxoSmithKline Biologicals SA Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102869378A (zh) * 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN103124737A (zh) * 2010-03-11 2013-05-29 葛兰素史密丝克莱恩生物有限公司 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗
BR112012022896A2 (pt) 2010-03-18 2018-03-27 Novartis Ag vacinas adjuvantes para meningococos do sorogrupo b
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
AU2013202310C1 (en) * 2010-03-29 2017-01-05 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
US20120128701A1 (en) 2010-09-09 2012-05-24 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
EP2622078B1 (en) * 2010-09-28 2014-11-05 Abera Bioscience AB Fusion protein for secretory protein expression
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
WO2013006055A1 (en) 2011-07-07 2013-01-10 De Staat Der Nederlanden, Vert. Door De Minister Van Vws A process for detergent-free production of outer membrane vesicles
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
JP5698693B2 (ja) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
RU2644340C2 (ru) 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
US20160120818A1 (en) 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
WO2014138290A1 (en) * 2013-03-05 2014-09-12 Trudeau Institute, Inc. Compositions and methods for treating bacterial infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP3229835A1 (en) 2014-12-09 2017-10-18 Sanofi Pasteur Compositions comprising n. meningitidis proteins
EP3838918B1 (en) 2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
JP2020506221A (ja) 2017-01-04 2020-02-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
JP7596069B2 (ja) 2017-03-15 2024-12-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020094580A1 (en) * 2018-11-06 2020-05-14 Glaxosmithkline Biologicals Sa Immunogenic compositions
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
EP3975368A1 (de) 2020-09-25 2022-03-30 Wobben Properties GmbH Unterbrechungsfreie stromversorgung bei windenergieanlagen
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202203250D0 (en) 2022-03-09 2022-04-20 Glaxosmithkline Biologicals Sa Immunogenic compositions

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
DE2744721A1 (de) 1977-10-05 1979-04-19 Veba Chemie Ag Pulverfoermige ueberzugsmittel und deren anwendung
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US20020146764A1 (en) * 1985-03-28 2002-10-10 Chiron Corporation Expression using fused genes providing for protein product
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DK0539492T3 (da) 1990-07-16 2003-09-22 Univ North Carolina Antigene jernundertrykkelige proteiner fra N. meningitidis beslægtet med hemolysinfamilien af toksiner
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
JP3532563B2 (ja) 1990-08-23 2004-05-31 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅおよびＮｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ由来トランスフェリン結合蛋白質
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5652211A (en) 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
US5371186A (en) 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
DE69227898T2 (de) * 1991-03-14 1999-05-12 Imclone Systems, Inc., New York, N.Y. Rekombinante hybride porinepitope
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
JPH07503982A (ja) 1992-01-13 1995-04-27 アクゾ　ノーベル　ナムローゼ　フェンノートシャップ エンジニアリングプラスチックを伴うゴムの架橋
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
US5750110A (en) 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
CA2175332C (en) 1993-11-08 2009-04-07 Sheena M. Loosmore Haemophilus transferrin receptor genes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
IL123720A (en) * 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6440701B1 (en) 1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
CA2297374A1 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1999006781A1 (de) 1997-07-31 1999-02-11 Wilo Gmbh Latentwärmespeicher für ein kraftfahrzeug
TR200000416T2 (tr) 1997-08-15 2000-07-21 University Of Utrecht Neisseria loctoferrin bağlayıcı protein.
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
SG123535A1 (en) * 1998-01-14 2006-07-26 Chiron Srl Neisseria meningitidis antigens
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
KR100794394B1 (ko) 1998-04-07 2008-01-15 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1082435B1 (en) 1998-06-03 2006-10-04 GlaxoSmithKline Biologicals S.A. Proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9814902D0 (en) 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US6951652B2 (en) 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9820002D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
CN1338005A (zh) * 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
ES2246093T3 (es) 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
CA2348928C (en) 1998-11-03 2010-01-26 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn,Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
CA2372235A1 (en) * 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
MXPA01011047A (es) * 1999-04-30 2003-10-14 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
US6632636B1 (en) 1999-06-18 2003-10-14 Elitra Pharmaceuticals Inc. Nucleic acids encoding 3-ketoacyl-ACP reductase from Moraxella catarrahalis
GB2351515B (en) 1999-06-29 2002-09-11 Pandrol Ltd Adjustable railway rail fastening assembly and methods for use therewith
GB9917977D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918038D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9918302D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
GB9918208D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
EP1741784B1 (en) 1999-11-29 2010-03-10 Novartis Vaccines and Diagnostics S.r.l. 85kDa neisserial antigen
BR0107679A (pt) * 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
US20040092711A1 (en) * 2000-02-28 2004-05-13 Arico Maria Beatrice Hybrid expression of neisserial proteins
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002330681C1 (en) * 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
DE60236596D1 (de) * 2001-07-27 2010-07-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0213119A (pt) * 2001-10-03 2004-12-28 Chiron Corp Composição imunogênica e uso da mesma
PL216662B1 (pl) * 2002-08-02 2014-04-30 Glaxosmithkline Biolog Sa Preparat immunogenny
WO2004032958A1 (en) * 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2885040C (en) * 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
BRPI0713904A2 (pt) * 2006-06-29 2013-06-25 Novartis Ag polipeptÍdeos a partir de neisseria meningitidis

Also Published As

Publication number Publication date
WO2004015099A3 (en) 2004-04-22
PL399492A1 (pl) 2012-11-19
DE20321890U1 (de) 2012-03-12
US20120027800A1 (en) 2012-02-02
KR20110036642A (ko) 2011-04-07
EP2258384A2 (en) 2010-12-08
CN1674933B (zh) 2012-09-26
IL166433A (en) 2011-08-31
KR20080078082A (ko) 2008-08-26
US20160082097A1 (en) 2016-03-24
CA2493977A1 (en) 2004-02-19
EP2481419A2 (en) 2012-08-01
EP2258385A3 (en) 2012-01-18
IL213264A0 (en) 2011-07-31
MY149591A (en) 2013-09-13
KR20050028051A (ko) 2005-03-21
EP2258384A3 (en) 2011-12-28
AU2008202479B2 (en) 2011-09-22
US8221770B2 (en) 2012-07-17
EP2258387A3 (en) 2011-10-19
AU2003253375A1 (en) 2004-02-25
AU2008202479A1 (en) 2008-06-26
EP1524991A1 (en) 2005-04-27
PL216662B1 (pl) 2014-04-30
TW200408406A (en) 2004-06-01
US20060034854A1 (en) 2006-02-16
KR101140033B1 (ko) 2012-05-07
WO2004014417A3 (en) 2004-07-22
CA2489030A1 (en) 2004-02-19
DK1524993T3 (da) 2013-06-03
MXPA05000842A (es) 2005-04-28
KR20050039839A (ko) 2005-04-29
AU2003260357A1 (en) 2004-02-25
EP2255826A3 (en) 2012-03-28
CY1114243T1 (el) 2015-12-09
US20060051379A1 (en) 2006-03-09
PT2255826E (pt) 2016-06-08
JP2006500963A (ja) 2006-01-12
EP1524992B1 (en) 2015-03-04
LU92262I2 (fr) 2013-09-30
JP2011051997A (ja) 2011-03-17
EP1524993A2 (en) 2005-04-27
AU2008202479C1 (en) 2014-01-16
CA2493124A1 (en) 2004-02-19
SI1524993T1 (sl) 2013-07-31
KR101237329B1 (ko) 2013-02-28
EP2255826A2 (en) 2010-12-01
NZ537181A (en) 2007-01-26
NZ574530A (en) 2010-12-24
JP2006506467A (ja) 2006-02-23
ES2575014T3 (es) 2016-06-23
CA2493092A1 (en) 2004-02-19
EP2258386A2 (en) 2010-12-08
IS7593A (is) 2004-12-13
CN1674933A (zh) 2005-09-28
ES2408251T3 (es) 2013-06-19
US20120064120A1 (en) 2012-03-15
PT1524993E (pt) 2013-06-12
EP2255826B1 (en) 2016-04-13
MXPA05001265A (es) 2005-04-28
CO5680455A2 (es) 2006-09-29
PL375408A1 (en) 2005-11-28
EP2258385A2 (en) 2010-12-08
JP2006500962A (ja) 2006-01-12
JP5409986B2 (ja) 2014-02-05
EP2258387A2 (en) 2010-12-08
IS7601A (is) 2004-12-16
US20120064119A1 (en) 2012-03-15
HK1077014A1 (en) 2006-02-03
CN1671413A (zh) 2005-09-21
JP2006505628A (ja) 2006-02-16
PL375407A1 (en) 2005-11-28
NZ587398A (en) 2012-03-30
PL220107B1 (pl) 2015-08-31
PL399214A1 (pl) 2012-11-19
EP1524990A2 (en) 2005-04-27
KR101139976B1 (ko) 2012-05-08
JP2011142916A (ja) 2011-07-28
AU2008255270A1 (en) 2009-01-08
US20110033500A1 (en) 2011-02-10
JP5414651B2 (ja) 2014-02-12
AU2003269864A1 (en) 2004-02-25
WO2004014417A2 (en) 2004-02-19
US20060240045A1 (en) 2006-10-26
EP1961427A3 (en) 2009-11-04
PL375382A1 (en) 2005-11-28
AU2003250204B8 (en) 2008-07-10
JP2012107036A (ja) 2012-06-07
AU2003250204A1 (en) 2004-02-25
DK2255826T3 (en) 2016-06-20
NO20050421L (no) 2005-03-30
AU2003260357B2 (en) 2009-10-29
NZ537904A (en) 2008-03-28
EP1524993B1 (en) 2013-03-06
WO2004014418A2 (en) 2004-02-19
EP1961427A2 (en) 2008-08-27
EP2258386A3 (en) 2011-11-02
EP2481419A3 (en) 2013-04-10
AU2003253375B2 (en) 2009-07-02
CO5680454A2 (es) 2006-09-29
CO5680456A2 (es) 2006-09-29
CY1117643T1 (el) 2017-04-26
NO20050008L (no) 2005-04-28
US7838014B2 (en) 2010-11-23
JP5789203B2 (ja) 2015-10-07
US20060057160A1 (en) 2006-03-16
MXPA05001349A (es) 2005-04-28
WO2004014418A3 (en) 2004-07-22
ES2537737T3 (es) 2015-06-11
CY2013036I2 (el) 2015-12-09
KR101239242B1 (ko) 2013-03-11
IS7658A (is) 2005-01-20
WO2004015099A2 (en) 2004-02-19
AU2003250204B2 (en) 2008-06-19
KR20050042143A (ko) 2005-05-04
IL166433A0 (en) 2006-01-15
JP4740738B2 (ja) 2011-08-03
CY2013036I1 (el) 2015-12-09
KR20120036996A (ko) 2012-04-18
DE20321889U1 (de) 2012-03-12
HUE029200T2 (en) 2017-03-28
IL165660A0 (en) 2006-01-15
NO20050010L (no) 2005-02-09
WO2004014419A1 (en) 2004-02-19
CA2493124C (en) 2014-04-29
EP1524992A2 (en) 2005-04-27
TWI360424B (en) 2012-03-21

Similar Documents

Publication Publication Date Title
SI2255826T1 (sl) Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
HK1074846A1 (en) Immunogenic compositions
IL188834A0 (en) Novel vaccine composition
IL227966A0 (en) Vaccination kit
GB0323965D0 (en) Immunogenic compositions
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
IL174542A0 (en) Immunogenic compositions
AU2003270779A8 (en) Vaccine compositions and adjuvant
GB0202901D0 (en) Novel vaccine
HUP0303942A3 (en) Novel vaccine composition
GB0218921D0 (en) Novel vaccine
TWI346555B (en) Vaccine composition
AU2003250828A8 (en) Immunogenic compositions
HK1087630A1 (en) Subcutaneously-administered ganglioside-based vaccine compositions
IL165756A0 (en) Neisserial vaccine compositions comprising a combination of antigens
GB0218037D0 (en) Vaccine composition
TWI346556B (en) Vaccine composition
GB0204116D0 (en) Novel vaccine composition
GB0230164D0 (en) Vaccine composition
GB0230168D0 (en) Vaccine composition
GB0218258D0 (en) Vaccine composition
GB0218051D0 (en) Vaccine composition
IL165693A0 (en) Vaccine composition
GB0218035D0 (en) Vaccine composition